Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
